Peri-operative chemotherapy for resectable colorectal liver metastasis

Does timing of systemic therapy matter?

Hugo Pinto Marques, Eduardo Barroso, Mechteld C. De Jong, Michael A. Choti, Vasco Ribeiro, Ana Marta Nobre, Carlos Carvalho, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Background The benefit of pre-operative chemotherapy in patients with resectable colorectal liver metastases (CRLM) remains ill defined. We sought to evaluate the impact of peri-operative systemic chemotherapy timing on outcome following resection of CRLM. Methods 676 patients who underwent surgery for CRLM were identified from two hepatobiliary center databases. Data were collected and analyzed utilizing multivariate, matched, and propensity-score analyses. Results Median number of metastases was 2 and median tumor size was 3.3 cm. 334 patients (49.4%) received pre-operative chemotherapy while 342(50.6%) did not. Surgical treatment was resection only (n = 555; 82.1%; minor hepatectomy, n = 399; 59.1%). While there was no difference in morbidity following minor liver resection (pre-operative chemotherapy: 17.9% versus no pre-operative chemotherapy: 16.5%; P = 0.72), morbidity was higher after major hepatic resection (pre-operative chemotherapy: 23.1% versus no pre-operative chemotherapy: 14.2%; P = 0.06). Patients treated with pre-operative chemotherapy had worse 5-year survival (43%) as compared to patients not treated with pre-operative chemotherapy (55%)(P = 0.009). Controlling for baseline characteristics, pre-operative chemotherapy was not associated with outcome on multivariate (HR = 1.04, P = 0.87) or propensity-score analysis (HR = 1.40, P = 0.12). Conclusion Pre-operative chemotherapy was associated with a trend toward increased morbidity among patients undergoing a major hepatic resection. Receipt of pre-operative chemotherapy was associated with neither an advantage nor disadvantage in terms of long-term survival. J. Surg. Oncol. 2012; 105:511-519.

Original languageEnglish (US)
Pages (from-to)511-519
Number of pages9
JournalJournal of Surgical Oncology
Volume105
Issue number6
DOIs
StatePublished - May 2012

Fingerprint

Neoplasm Metastasis
Drug Therapy
Liver
Therapeutics
Propensity Score
Morbidity
Colorectal Surgery
Survival
Hepatectomy
Databases
Neoplasms

Keywords

  • chemotherapy
  • colorectal
  • liver
  • metastasis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Pinto Marques, H., Barroso, E., De Jong, M. C., Choti, M. A., Ribeiro, V., Nobre, A. M., ... Pawlik, T. M. (2012). Peri-operative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter? Journal of Surgical Oncology, 105(6), 511-519. https://doi.org/10.1002/jso.22133

Peri-operative chemotherapy for resectable colorectal liver metastasis : Does timing of systemic therapy matter? / Pinto Marques, Hugo; Barroso, Eduardo; De Jong, Mechteld C.; Choti, Michael A.; Ribeiro, Vasco; Nobre, Ana Marta; Carvalho, Carlos; Pawlik, Timothy M.

In: Journal of Surgical Oncology, Vol. 105, No. 6, 05.2012, p. 511-519.

Research output: Contribution to journalArticle

Pinto Marques, H, Barroso, E, De Jong, MC, Choti, MA, Ribeiro, V, Nobre, AM, Carvalho, C & Pawlik, TM 2012, 'Peri-operative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter?', Journal of Surgical Oncology, vol. 105, no. 6, pp. 511-519. https://doi.org/10.1002/jso.22133
Pinto Marques, Hugo ; Barroso, Eduardo ; De Jong, Mechteld C. ; Choti, Michael A. ; Ribeiro, Vasco ; Nobre, Ana Marta ; Carvalho, Carlos ; Pawlik, Timothy M. / Peri-operative chemotherapy for resectable colorectal liver metastasis : Does timing of systemic therapy matter?. In: Journal of Surgical Oncology. 2012 ; Vol. 105, No. 6. pp. 511-519.
@article{812ac0b5654f488b876b5e2180609e77,
title = "Peri-operative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter?",
abstract = "Background The benefit of pre-operative chemotherapy in patients with resectable colorectal liver metastases (CRLM) remains ill defined. We sought to evaluate the impact of peri-operative systemic chemotherapy timing on outcome following resection of CRLM. Methods 676 patients who underwent surgery for CRLM were identified from two hepatobiliary center databases. Data were collected and analyzed utilizing multivariate, matched, and propensity-score analyses. Results Median number of metastases was 2 and median tumor size was 3.3 cm. 334 patients (49.4{\%}) received pre-operative chemotherapy while 342(50.6{\%}) did not. Surgical treatment was resection only (n = 555; 82.1{\%}; minor hepatectomy, n = 399; 59.1{\%}). While there was no difference in morbidity following minor liver resection (pre-operative chemotherapy: 17.9{\%} versus no pre-operative chemotherapy: 16.5{\%}; P = 0.72), morbidity was higher after major hepatic resection (pre-operative chemotherapy: 23.1{\%} versus no pre-operative chemotherapy: 14.2{\%}; P = 0.06). Patients treated with pre-operative chemotherapy had worse 5-year survival (43{\%}) as compared to patients not treated with pre-operative chemotherapy (55{\%})(P = 0.009). Controlling for baseline characteristics, pre-operative chemotherapy was not associated with outcome on multivariate (HR = 1.04, P = 0.87) or propensity-score analysis (HR = 1.40, P = 0.12). Conclusion Pre-operative chemotherapy was associated with a trend toward increased morbidity among patients undergoing a major hepatic resection. Receipt of pre-operative chemotherapy was associated with neither an advantage nor disadvantage in terms of long-term survival. J. Surg. Oncol. 2012; 105:511-519.",
keywords = "chemotherapy, colorectal, liver, metastasis",
author = "{Pinto Marques}, Hugo and Eduardo Barroso and {De Jong}, {Mechteld C.} and Choti, {Michael A.} and Vasco Ribeiro and Nobre, {Ana Marta} and Carlos Carvalho and Pawlik, {Timothy M.}",
year = "2012",
month = "5",
doi = "10.1002/jso.22133",
language = "English (US)",
volume = "105",
pages = "511--519",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Peri-operative chemotherapy for resectable colorectal liver metastasis

T2 - Does timing of systemic therapy matter?

AU - Pinto Marques, Hugo

AU - Barroso, Eduardo

AU - De Jong, Mechteld C.

AU - Choti, Michael A.

AU - Ribeiro, Vasco

AU - Nobre, Ana Marta

AU - Carvalho, Carlos

AU - Pawlik, Timothy M.

PY - 2012/5

Y1 - 2012/5

N2 - Background The benefit of pre-operative chemotherapy in patients with resectable colorectal liver metastases (CRLM) remains ill defined. We sought to evaluate the impact of peri-operative systemic chemotherapy timing on outcome following resection of CRLM. Methods 676 patients who underwent surgery for CRLM were identified from two hepatobiliary center databases. Data were collected and analyzed utilizing multivariate, matched, and propensity-score analyses. Results Median number of metastases was 2 and median tumor size was 3.3 cm. 334 patients (49.4%) received pre-operative chemotherapy while 342(50.6%) did not. Surgical treatment was resection only (n = 555; 82.1%; minor hepatectomy, n = 399; 59.1%). While there was no difference in morbidity following minor liver resection (pre-operative chemotherapy: 17.9% versus no pre-operative chemotherapy: 16.5%; P = 0.72), morbidity was higher after major hepatic resection (pre-operative chemotherapy: 23.1% versus no pre-operative chemotherapy: 14.2%; P = 0.06). Patients treated with pre-operative chemotherapy had worse 5-year survival (43%) as compared to patients not treated with pre-operative chemotherapy (55%)(P = 0.009). Controlling for baseline characteristics, pre-operative chemotherapy was not associated with outcome on multivariate (HR = 1.04, P = 0.87) or propensity-score analysis (HR = 1.40, P = 0.12). Conclusion Pre-operative chemotherapy was associated with a trend toward increased morbidity among patients undergoing a major hepatic resection. Receipt of pre-operative chemotherapy was associated with neither an advantage nor disadvantage in terms of long-term survival. J. Surg. Oncol. 2012; 105:511-519.

AB - Background The benefit of pre-operative chemotherapy in patients with resectable colorectal liver metastases (CRLM) remains ill defined. We sought to evaluate the impact of peri-operative systemic chemotherapy timing on outcome following resection of CRLM. Methods 676 patients who underwent surgery for CRLM were identified from two hepatobiliary center databases. Data were collected and analyzed utilizing multivariate, matched, and propensity-score analyses. Results Median number of metastases was 2 and median tumor size was 3.3 cm. 334 patients (49.4%) received pre-operative chemotherapy while 342(50.6%) did not. Surgical treatment was resection only (n = 555; 82.1%; minor hepatectomy, n = 399; 59.1%). While there was no difference in morbidity following minor liver resection (pre-operative chemotherapy: 17.9% versus no pre-operative chemotherapy: 16.5%; P = 0.72), morbidity was higher after major hepatic resection (pre-operative chemotherapy: 23.1% versus no pre-operative chemotherapy: 14.2%; P = 0.06). Patients treated with pre-operative chemotherapy had worse 5-year survival (43%) as compared to patients not treated with pre-operative chemotherapy (55%)(P = 0.009). Controlling for baseline characteristics, pre-operative chemotherapy was not associated with outcome on multivariate (HR = 1.04, P = 0.87) or propensity-score analysis (HR = 1.40, P = 0.12). Conclusion Pre-operative chemotherapy was associated with a trend toward increased morbidity among patients undergoing a major hepatic resection. Receipt of pre-operative chemotherapy was associated with neither an advantage nor disadvantage in terms of long-term survival. J. Surg. Oncol. 2012; 105:511-519.

KW - chemotherapy

KW - colorectal

KW - liver

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=84859715398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859715398&partnerID=8YFLogxK

U2 - 10.1002/jso.22133

DO - 10.1002/jso.22133

M3 - Article

VL - 105

SP - 511

EP - 519

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -